Ventyx Biosciences, Inc. (VTYX)
- Previous Close
4.0900 - Open
4.1600 - Bid 4.1100 x 100
- Ask 4.1400 x 400
- Day's Range
4.0600 - 4.6739 - 52 Week Range
1.8650 - 40.5800 - Volume
814,706 - Avg. Volume
3,986,631 - Market Cap (intraday)
290.457M - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
-- - EPS (TTM)
-3.2400 - Earnings Date Mar 25, 2024 - Mar 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.70
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
ventyxbio.comRecent News: VTYX
Performance Overview: VTYX
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VTYX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VTYX
Valuation Measures
Market Cap
290.46M
Enterprise Value
-630.75k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.95
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.91%
Return on Equity (ttm)
-56.76%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-192.6M
Diluted EPS (ttm)
-3.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
302.58M
Total Debt/Equity (mrq)
3.74%
Levered Free Cash Flow (ttm)
-109.9M
Research Analysis: VTYX
Company Insights: VTYX
VTYX does not have Company Insights